DURHAM, N.C.–(BUSINESS WIRE)–Nuventra Pharma Sciences is pleased to announce the addition of Iftekhar Mahmood, Ph.D., to its growing team of
Abu Dhabi-based pharmaceutical manufacturer Neopharma and US-based Elevar Therapeutics formed a 50-50 joint venture in UAE, to organize selling Rivoceranib, a targeted anticancer drug and conduct clinical trials for other pipeline candidates.
The FDA has accepted for review Foamix’s New Drug Application (NDA) for FMX103 (minocycline topical foam 1.5%) topical foam, for the treatment of moderate-to-severe papulopustular rosacea in adults.
Takeda said Tuesday it will sell certain OTC and non-core assets for over $200 million to ACino, to accelerate deleveraging as it said it will simplify portfolio in Takeda’s NEMEA region.
HAYWARD, Calif.–(BUSINESS WIRE)–#Africa–Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MAGBIO
Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society
Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments, along with patient survey results and post hoc efficacy results following the 1-year Phase III HALO long-term study
Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity – two common nerve agents
Nexien BioPharma was granted patent for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office.
@BiondVax Pharmaceuticals has enrolled first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal #flu #vaccine candidate.
Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb FOCUS study of Fremanezumab in Adults with Migraine
These results include reduction in monthly average migraine days; reduction in migraine related symptoms; and improvements in depression status; work productivity and activity impairment.
Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.